PTC Therapeutics | PTCT - Sales Revenues


PTC Therapeutics reported $361M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 307.96M 39.9M Jun/2026
Alnylam Pharmaceuticals USD 1.29B 120M Jun/2026
Amgen USD 10.1B 1.48B Jun/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
Biogen USD 2.74B 490M Jun/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Cytokinetics USD 28.6M 9.25M Jun/2026
Daiichi Sankyo JPY 574.74B 12.26B Jun/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Gilead Sciences USD 7.8B 800M Jun/2026
Incyte USD 1.67B 400M Jun/2026
Ionis Pharmaceuticals USD 268M 22M Jun/2026
Ironwood Pharmaceuticals USD 113.04M 6.53M Jun/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
Novartis USD 14.41B 1.3B Jun/2026
Pfizer USD 15.03B 530M Jun/2026
PTC Therapeutics USD 361M 88M Jun/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Roche Holding CHF 30.36B 14.71B Jun/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Sarepta Therapeutics USD 401.3M 329.5M Jun/2026
TG Therapeutics USD 240.34M 45.54M Jun/2026
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026
Xencor USD 51.22M 46.71M Jun/2026